VibroSense redovisade en nettoomsättning om 0,27 MSEK (0,55) i kvartalet, motsvarande en minskning m...
Redeye is impressed by the strong delivery from GomSpace during the last two quarters, posting stell...
Redeye initiates coverage of BICO, a leading player in the bioconvergence space.
Redeye provides a research update on Faron Pharmaceuticals following the company’s recent H1 report.
* Europe and other markets continue to perform, North America less so * We reset our expectations-po...
Q2-rapporten överraskade positivt med stark orderingång och förbättrad lönsamhet, även om nettoomsät...
Redeye comments on BioInvent’s Q2 report 2025. New positive results with BI-1206 in solid tumours an...
Nettoomsättningen för det andra kvartalet 2025 uppgick till 142,1 MSEK (114,2), motsvarande en organ...
New Wave Groups Q2-rapport var svagare än väntat med lägre omsättning och resultat, främst tyngt av ...
Redeye returns with an update following AlzeCure's Q2 earnings release, which aligned with our expec...
* Pome project schedule delayed * Lower-than-expected project margins in Pome and Pienava * We cut '...
Redeye notes that Smart Eye’s Q2 reflected underlying solid performance, with Smart Eye reaching a k...
* Orders -10%, sales +3%, adj. EBITA -6% vs. ABGSCe * Enedo drove EBITA miss, Inission beat; Enedo b...
Redeye provides an update following Corline’s Q2 2025 report.
* Scale and presence underpin growth and margin expansion * Sharper execution on cross-segment syner...
